Welcome to our dedicated page for Scisparc news (Ticker: SPRC), a resource for investors and traders seeking the latest updates and insights on Scisparc stock.
SciSparc Ltd. (SPRC) is a clinical-stage pharmaceutical innovator developing cannabinoid-based therapies for neurological disorders while operating a consumer hemp products division. This page provides verified updates on both business segments, serving investors and stakeholders with essential news repository.
Access authoritative information on SPRC's clinical trial advancements, regulatory filings, and financial performance alongside developments in its hemp-derived product line. Content includes press releases detailing research milestones, partnership announcements, and strategic initiatives across therapeutic and consumer markets.
Key updates cover FDA communications, intellectual property developments, quarterly earnings disclosures, and operational expansions. All materials are curated to meet investor needs for decision-making clarity while maintaining compliance with financial reporting standards.
Bookmark this resource for streamlined access to SPRC's official announcements and analysis. Regularly updated content ensures stakeholders stay informed about the company's progress in pharmaceutical innovation and consumer market execution.
SciSparc Ltd. (NASDAQ: SPRC) announced the successful manufacturing of clinical batches for its drug candidate SCI-110, intended for a Phase IIb trial targeting Tourette Syndrome. The manufacturing was done by Procaps Group under stringent Good Manufacturing Practices, ensuring compliance with FDA and European Medicines Agency standards. Ethics approvals have been secured from institutions in Germany and Israel, with plans to obtain further approval from Yale University. The trial aims to assess the efficacy and safety of SCI-110 in adults aged 18-65, following a randomized, placebo-controlled method. Successful trial outcomes could advance SciSparc's focus on cannabinoid pharmaceuticals.
SciSparc Ltd. (Nasdaq: SPRC) announced an agreement with Tikun Olam Cannbit Pharmaceuticals to supply CBD-rich oil for its proprietary SCI-210 treatment. This treatment, combining CBD and CannAmide™, will be evaluated in a clinical trial for children with autism spectrum disorder (ASD) at Soroka University Medical Center. The randomized, double-blind trial will assess safety, tolerability, and efficacy in 60 children over 20 weeks, utilizing key measures like the Aberrant Behavior Checklist-Community. The company received necessary approvals from the Israeli Ministry of Health and the Ethics Committee for the trial.
SciSparc Ltd. (Nasdaq: SPRC) has entered into a definitive agreement to sell a 49% stake in its subsidiary, SciSparc Nutraceuticals Inc., to Jeffs' Brands Ltd. (Nasdaq: JFBR) for $2.5 million in cash, along with potential inventory adjustments worth around $300,000. The deal includes a mutual share exchange valued at $300,000. Following completion, expected within seven business days, SciSparc will retain about 51% of the subsidiary. A consulting agreement will also be established, allowing Jeffs' Brands to manage Wellution products for a monthly fee.
The Wellution brand is recognized on Amazon for its hemp-based products, boasting positive reviews and rankings.
SciSparc Ltd. (Nasdaq: SPRC) announced its ongoing collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) to develop novel psychedelic-derived therapeutics. Clearmind filed three provisional patent applications with the USPTO, focusing on unique combinations of MDMA, Ibogaine, and Ketamine with SciSparc's CannAmide™ (PEA). In total, six patent applications have been submitted related to alcohol use disorder, cocaine addiction, obesity, and other metabolic disorders. Both companies will jointly own any generated assets. The collaboration enhances SciSparc's intellectual property portfolio as it develops treatments for CNS disorders, including multiple drug candidates for various conditions.
SciSparc Ltd. (Nasdaq: SPRC) announced the successful establishment of its MitoCareX Bio joint venture's cloud-based computing infrastructure, a key milestone under the March 2022 agreement. This development aims to enhance drug discovery for cancer and rare diseases by utilizing machine learning to investigate mitochondrial carriers. Following this achievement, SciSparc will invest an additional $400,000, increasing its ownership in MitoCareX Bio from 31.48% to 41.92%. The venture is currently advancing its computational drug discovery platform, supported by previous successful proof-of-concept experiments in the UK.
SciSparc Ltd. (Nasdaq: SPRC), a clinical-stage pharmaceutical company, announced on Feb 15, 2023, the filing of three provisional patent applications by its collaborator, Clearmind Medicine Inc. (Nasdaq: CMND). These patents cover innovative combinations of psychedelic compounds such as LSD, psilocybin, and DMT with SciSparc's CannAmide™. The collaboration aims to develop therapies for alcohol use disorder, cocaine addiction, and obesity. CEO Oz Adler expressed confidence in the partnership, highlighting CannAmide™'s ability to enhance treatment efficacy while minimizing dosages.
SciSparc Ltd. (Nasdaq: SPRC), a clinical-stage pharmaceutical company, announced a restructuring plan to transfer its pharmaceutical operations to a new wholly-owned subsidiary. This move aims to facilitate a possible public listing of the subsidiary while retaining a controlling interest in its core activities. The restructuring is expected to enhance value creation opportunities and allow SciSparc to explore new investments across various sectors. The company is currently developing cannabinoid-based therapies targeting disorders such as Tourette Syndrome, Alzheimer's disease, pain management, and autism spectrum disorder.
SciSparc Ltd. (Nasdaq: SPRC) is evaluating measures to address potential illegal short sales affecting its ordinary shares. The company's board believes these actions have artificially depressed its stock price. To combat this, SciSparc plans to engage third-party professionals to analyze trading patterns, following the lead of companies like Helbiz and Genius Group. The firm continues focusing on its clinical-stage pharmaceutical development initiatives, particularly therapies for central nervous system disorders such as Alzheimer's and Tourette syndrome.
SciSparc Ltd. (Nasdaq: SPRC) has received approval from Soroka University Medical Center to conduct a clinical trial for its proprietary treatment SCI-210 in patients with autism spectrum disorder (ASD). The trial, approved by the Israeli Ministry of Health and the Ethics Committee, will evaluate the safety and efficacy of SCI-210, a combination of cannabidiol and CannAmide™, in comparison to CBD monotherapy. This randomized, double-blind, placebo-controlled study will involve 60 children over 20 weeks, focusing on several key efficacy endpoints, including behavior assessments and therapeutic dosing.
SciSparc Ltd. (Nasdaq: SPRC) has announced promising results from pre-clinical studies on its collaboration with Clearmind Medicine Inc. regarding the drug candidate MEAI for cocaine addiction treatment. The studies indicate that MEAI may effectively reduce cravings without disrupting natural reward processes.
Conducted by Professor Gal Yadid at Bar Ilan University, the research suggests MEAI maintains natural rewards while addressing drug-seeking behavior. A provisional patent application for MEAI’s use in treating cocaine addiction was filed in June 2022, linking SciSparc's CannAmide™ with Clearmind’s MEAI.
FAQ
What is the current stock price of Scisparc (SPRC)?
What is the market cap of Scisparc (SPRC)?
